4.3 Article Proceedings Paper

MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation

Journal

IMMUNOBIOLOGY
Volume 211, Issue 6-8, Pages 619-625

Publisher

ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.imbio.2006.05.005

Keywords

CLIP; HLA-DM; HLA-DO; HLA-DR; invariant chain; MHC class II; tumour antigen presentation; tumour immunology; vaccination

Categories

Ask authors/readers for more resources

MHC class II molecules presenting MHC class II restricted antigens play an important role in the activation of CD4+ T cells, which are the central orchestrating cells of an immune response. This review focuses on the particular role of MHC class II molecules in tumour immunology. The MHC class II antigen presentation pathway and the expression of MHC class II molecules on tumour cells related to clinical outcome is discussed. Improving the MHC class II tumour antigen presentation pathway, for instance by downregulation. of the invariant chain or modulation of HLA-DO expression, offers many opportunities for developing new modalities of immunotherapy. (c) 2006 Elsevier GmbH. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available